Combined whole-body dynamic and static PET/CT with low-dose [ 18 F]PSMA-1007 in prostate cancer patients.

Christos SachpekidisLeyun PanMartin GroezingerDimitrios Stefanos StraussAntonia Dimitrakopoulou-Strauss

Published in: European journal of nuclear medicine and molecular imaging (2024)

F]PSMA-1007 in both tumor lesions and normal organs at the whole-body level. These findings unfold many of the potentials of the new LAFOV PET/CT technology in the field of PSMA-based diagnosis and theranostics of prostate cancer.

Keyphrases

pet ct
prostate cancer
low dose
radical prostatectomy
end stage renal disease
positron emission tomography
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
peritoneal dialysis
high dose
pet imaging